Following a review of four published observational studies, the US FDA has issued a statement

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1335, 2011-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The US FDA has issued a statement on the use of conjugated estrogens/medroxyprogesterone

Inpharma, Vol. 1, Iss. 1359, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Tiratricol warning issued by US FDA

Inpharma, Vol. 1, Iss. 1266, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

The US FDA has issued a Talk Paper advising of changes to the US Strattera [atomoxetine] labelling

Reactions Weekly, Vol. 1, Iss. 1033, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The US FDA has issued a nationwide alert warning consumers not to use Liqiang 4 Dietary Supplement Capsules

Inpharma, Vol. 1, Iss. 1495, 2005-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

The US FDA has published the final Requirements for Submission of Labeling for Human Prescription Drugs and Biologics in Electronic Format rule

Inpharma, Vol. 1, Iss. 1418, 2003-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite